During the past decade, Markhot Ferenc Oktatokorhaz es Rendelointezet conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 13 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 11 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Markhot Ferenc Oktatokorhaz es Rendelointezet" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "Allergan" with 4 trials sponsored, "Anthos Therapeutics, Inc." with 2 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored and "Gilead Sciences" with 2 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Markhot Ferenc Oktatokorhaz es Rendelointezet" #1 collaborator was "GlaxoSmithKline" with 2 trials as a collaborator, "Itreas" with 2 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Instituto Grifols, S.A." with 1 trials as a collaborator and "Quintiles, Inc." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Markhot Ferenc Oktatokorhaz es Rendelointezet" are "Diabetes Mellitus" (4 trials), "Gastroparesis" (4 trials), "Rheumatoid Arthritis" (3 trials), "Type 2 Diabetes Mellitus" (3 trials) and "Ulcerative Colitis" (3 trials). Many other conditions were trialed in "Markhot Ferenc Oktatokorhaz es Rendelointezet" in a lesser frequency.

Most popular intervention types in "Markhot Ferenc Oktatokorhaz es Rendelointezet" are "Drug" (28 trials), "Biological" (6 trials), "Behavioral" (2 trials), "Other" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Relamorelin" (3 trials), "Abelacimab" (2 trials), "Diet" (2 trials) and "Etrolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Markhot Ferenc Oktatokorhaz es Rendelointezet" are 33 trials for "All" genders.

Currently, there are NaN active trials in "Markhot Ferenc Oktatokorhaz es Rendelointezet". undefined are not yet recruiting, 6 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Markhot Ferenc Oktatokorhaz es Rendelointezet, 1 suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Markhot Ferenc Oktatokorhaz es Rendelointezet, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".